### **Accepted Manuscript**

Title: Developmental milestones in type I spinal muscular atrophy

Author: Roberto De Sanctis, Giorgia Coratti, Amy Pasternak, Jacqueline Montes, Marika Pane, Elena S. Mazzone, Sally Dunaway Young, Rachel Salazar, Janet Quigley, Maria C. Pera, Laura Antonaci, Leonardo Lapenta, Allan M. Glanzman, Danilo Tiziano, Francesco Muntoni, Basil T. Darras, Darryl C. De Vivo, Richard Finkel, Eugenio Mercuri


PII: S0960-8966(16)30816-1

DOI: http://dx.doi.org/doi: 10.1016/j.nmd.2016.10.002

Reference: NMD 3270

To appear in: Neuromuscular Disorders

Received date: 14-7-2016 Accepted date: 2-10-2016



Please cite this article as: Roberto De Sanctis, Giorgia Coratti, Amy Pasternak, Jacqueline Montes, Marika Pane, Elena S. Mazzone, Sally Dunaway Young, Rachel Salazar, Janet Quigley, Maria C. Pera, Laura Antonaci, Leonardo Lapenta, Allan M. Glanzman, Danilo Tiziano, Francesco Muntoni, Basil T. Darras, Darryl C. De Vivo, Richard Finkel, Eugenio Mercuri, Developmental milestones in type I spinal muscular atrophy, *Neuromuscular Disorders* (2016), http://dx.doi.org/doi: 10.1016/j.nmd.2016.10.002.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1, De Sanctis et al.

### Developmental milestones in type I spinal muscular atrophy

Roberto De Sanctis<sup>a</sup>, Giorgia Coratti<sup>a</sup>, Amy Pasternak<sup>b</sup>, Jacqueline Montes<sup>c</sup>, Marika Pane<sup>a</sup>,

Elena S. Mazzone<sup>a</sup>, Sally Dunaway Young<sup>c</sup>, Rachel Salazar<sup>c</sup>, Janet Quigley<sup>b</sup>, Maria C.

Pera<sup>a</sup>, Laura Antonaci<sup>a</sup>, Leonardo Lapenta<sup>a</sup>, Allan M. Glanzman<sup>d</sup>, Danilo Tiziano<sup>e,</sup>

Francesco Muntoni<sup>f</sup>, Basil T. Darras<sup>b</sup>, Darryl C. De Vivo<sup>c</sup>, Richard Finkel<sup>g</sup>, Eugenio Mercuri<sup>a</sup>

<sup>a</sup> Paediatric Neurology Unit, Catholic University and Centro Clinico Nemo, Rome, Italy

<sup>b</sup>Departments of Neurology, Boston Children's Hospital, Harvard Medical School, Boston,

USA

<sup>c</sup>Department of Neurology, Columbia University Medical Center, New York, USA

<sup>d</sup>Department of Physical Therapy, The Children's Hospital of Philadelphia, Philadelphia,

USA

<sup>e</sup>Institute of genetics, Catholic University, Rome, Italy.

<sup>f</sup>Dubowitz Neuromuscular Centre, UCL Institute of Child Health & Great Ormond Street

Hospital, London, UK

<sup>9</sup>Nemours Children's Hospital, University of Central Florida College of Medicine, Orlando,

USA

Corresponding author:

Eugenio Mercuri

Pediatric Neurology, Catholic University

Largo Gemelli 8, 00168 Rome, Italy

Tel.: +390630155340; fax: +390630154363

E-mail: eumercuri@gmail.com

2, De Sanctis et al.

Highlights

- The paper reports patterns of natural progression in type 1 SMA.
- This is the first time the HINE is used to capture possible changes motor developmental milestones in a neuromuscular population.
- Even with current standards of care, motor developmental milestones are rarely acquired, as part of natural history in type I SMA infants.

#### **Abstract**

The aim of this retrospective multicentric study was to assess developmental milestones longitudinally in type I SMA infants using the Hammersmith Infant Neurological Examination.

Thirty-three type I SMA infants, who classically do not achieve the ability to sit unsupported, were included in the study.

Our results confirmed that all patients had a score of 0 out of a scale of 4 on items assessing sitting, rolling, crawling, standing or walking. A score more than 0 was only achieved in three items: head control (n=13), kicking (n=15) and hand grasp (n=18). In these items, the maximal score achieved was 1 out of a scale of 4, indicating only partial achievement of the milestone. Infants with symptom onset after 6 months of age had longer preservation of the scores of 1 when compared to those with onset before 6 months of age.

Our results suggest that even when current standards of care are applied, developmental milestones are rarely even partially achieved as part of natural history in type I SMA infants. No infants in this study achieved a major milestone such as rolling over, or sitting independently, which would therefore represent robust outcomes in future interventional trials.

Keywords: Spinal Muscular Atrophy; Hammersmith Infant Neurological Examination;
Outcome measures; Motor milestones

3, De Sanctis et al.



4, De Sanctis et al.

#### 1 Introduction

Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disorder caused by mutations in the survival of motor neuron 1 (SMN1) telomeric gene, resulting in a reduced amount of functional full-length SMN protein. In children, SMA is classified into 3 phenotypes based on age at onset and maximal motor function achieved.[1,2] Type I SMA is characterized by inability to sit unsupported and by onset within 6 months of age. [2,3] Survival, typically limited to the first year, has increased in the last few decades, due to improvements in the standards of care, with the possibility to opt for respiratory and nutritional support. [4,5]

The increased survival and the advent of different therapeutic approaches have highlighted the need for a better definition of the natural history of type I SMA especially as far as the acquisition of functional milestones is concerned, and for identification of appropriate tools to follow the progression of the disease. A few attempts have been made recently to develop clinical tools specifically designed to assess motor function in weak infants, such as the CHOP INTEND[6], or to adapt existing scales, such as the TIMP. [7,8] These scales have helped to identify the variability of the phenotype and to assess the rapid progression of the disease. Little attempt has been made to monitor developmental milestones in these infants as, by definition, they are unable to sit and only a minority of them will acquire the milestones of head control and/ or rolling over which are subsequently lost. Other important milestones, such as crawling or standing are not achieved in type I SMA infants. However, no systematic study has assessed longitudinally the acquisition of motor milestones in type I SMA infants receiving current standards of care.

The aim of this study was to report the longitudinal use of a module capturing developmental milestones in infancy, performed as part of the Hammersmith Infant Neurological Examination (HINE) [9,10], in type I SMA infants. More specifically, we set

5, De Sanctis et al.

out to investigate whether developmental milestones are achieved at any stage during the first years of life in these infants and, if achieved, to assess possible changes over time.

#### 2. Material and Methods

This retrospective study was performed by collecting data from different existing large multicentric datasets, including one network based in the United States (the Pediatric Neuromuscular Clinical Research Network for SMA) and one in Italy, in the period between 2010 and October 2014.

All patients had a genetically confirmed diagnosis of SMA with a homozygous deletion of exon 7 in the *SMN1* gene, and a clinically confirmed diagnosis of type 1 SMA.

The diagnosis of SMA was made by the principal investigator at each site who also classified them according to the Dubowitz's decimal classification [11] and to the recently proposed classification in 3 subtypes [4,12]: type IA presentation at birth with joint contractures and need for respiratory support, or onset of motor and respiratory involvement in the first week; type IB, symptom onset after neonatal period, usually before age 3 months, head control never achieved; and type IC, onset after neonatal period, usually between 3 and 6 months, head control achieved.

Previously identified patients, followed in our clinics and newly diagnosed patients were enrolled. All eligible patients were offered participation. We included all infants who had at least two or more assessments over the following two years.

The study was approved by the individual institutional review boards at the participating sites.

Study visits were scheduled at baseline, when first assessed, and, when possible, every 2 to 3 months until the age of 12 months and every 6 months thereafter, depending on the infant's health and ability to travel.

6, De Sanctis et al.

The HINE [9], is a simple and scorable method for assessing infants between 2 and 24 months of age, including different aspects of neurological examinations as cranial nerves, posture, movements, tone and reflexes. A separate section includes eight selected motor items which document developmental progress (Figure 1). It provides a summary of motor developmental milestones giving not only the opportunity to record the age at which the various milestones were achieved but also allowing to quantify intermediate steps leading to the full achievement of the milestone. Each item provides the opportunity to score the level of development on a 5 point scale with 0 as absence of the activity. These milestones were designed according to the gradient of normal maturation, with normative values adapted from Illingworth's work [13]. These items are more granular than the World Health Organization's motor milestones, which captures sitting without support, hands-and-knees crawling, standing with assistance, standing alone, walking with assistance and walking alone. [14]

The HINE module, on the other hand is shorter and includes less items of the motor component of the Bayley scales of infants and toddler development that include many items that are not relevant to type 1 SMA and is more fatiguing for such fragile infants.

#### 2.1 Statistical analysis.

The distributions of scores was plotted for individual infants for each item plotting longitudinal results according to age.

#### 3. Results

Thirty-three infants fulfilled the inclusion criteria and were included in the study. Their age at onset ranged between 1 and 8 months. The age when they were first assessed was between 2 and 9 months.

7, De Sanctis et al.

Seven infants, who were at the severe end of the spectrum of weakness and had early presentation with motor and respiratory involvement within the first week, were classified as 1.1, using the Dubowitz decimal system, or as type 1A according to the recent classification. Two other infants, who achieved head control, were at the other end of the spectrum, and were classified as 1.9, or type 1C according to the recently proposed classification. In both, onset of signs was around 7-8 months.

Twenty-four infants had the more typical course of type I SMA, and were classified as 1.5, or type IB. In all 24 the onset was after the first week but before age 5-6 months. Two of these 24 achieved transient head control.

#### 3.1 Motor developmental milestones

#### 3.1.1 Head control

All 7 infants at the weakest end of the spectrum had scores of 0 on all the assessments. Among the 24 infants in the main group, 11 had a score of 1 (wobbles) on at least one assessment, 13 had scores of 0 on all assessments. None had scores of 2 or above (Figure 2).

Infants who had a score of 0 never achieved higher scores on subsequent assessments.

The 2 stronger infants with late onset had a score of 1 that persisted throughout the assessments over the following 2 years.

#### 3.1.2 Voluntary grasp

All 7 infants at the weakest end of the spectrum had scores of 0 on all the assessments. Among the 24 infants in the main group, 17 had a score of 1 (using whole hand) on at least one assessment, 7 had a score of 0 on all assessments. None had scores of 2 or above (Figure 3).

8, De Sanctis et al.

None of the infants who had a score of 0 on one assessment had better scores on the subsequent assessments.

The 2 stronger infants with late onset achieved a score of 1 that persisted throughout the assessments over the following 2 years.

#### 3.1.3 Ability to kick

All 7 infants at the weakest end of the spectrum had scores of 0 on all the assessments.

Among the 24 infants in the main group, 13 had a score of 1 (gravity-eliminated movements) on at least one assessment, 11 had scores of 0 on all assessments. None had scores of 2 or above (Figure 4). Only one of the infants who had a score of 0 achieved a score of 1 on subsequent assessments. The 2 stronger infants with late onset had a score of 1 that persisted throughout the assessments over the following 2 years.

#### 3.1.4 Other items

All the infants in this study had a score of 0 on all visits in all the remaining 5 items (sitting, rolling, crawling, standing, walking).

#### 3.1.5 Gastrostomy and ventilator support

In the main group, 15 of the 24 infants underwent gastrostomy for swallowing problems and /or failure to thrive, 10 started non-invasive ventilation and 5 had tracheostomy. None had any improvement following the introduction of any of these procedures. In the few patients in whom the scores on individual items were 1 at the time these procedures were introduced, the score of 1 was not always maintained (Figures 2, 3 and 4).

9, De Sanctis et al.

#### 4. Discussion

Improvements in standards of care with the more systematic use of optimal respiratory care including non-invasive ventilation and cough augmentation techniques and better management of nutritional issues have resulted in improved survival in type 1 SMA in the last decade. This has raised the question of whether the improved survival is also associated with possible acquisition of motor developmental milestones over time. In order to capture possible changes in the achievement of motor developmental milestones in infancy, we used a module extracted from the HINE, an assessment of global neurological function and motor developmental milestones in infants that can be used from the age of 2 -3 months. The HINE has already been used in several clinical groups [15] and has been validated in typically developing children [9]. Using the developmental module from the HINE we were able to confirm that motor developmental milestones are only rarely acquired in type 1 SMA infants after the diagnosis is made.

Not surprisingly, infants with the most severe phenotype who also had very early onset of clinical signs, never acquired any motor developmental milestones, showing a score of 0 on all of the 8 items at all times.

In contrast, scores higher than 0 could be observed in three of the items in the cohort of infants with onset after the first week of life.

By definition, type I SMA infants are unable to sit unsupported. Our results confirmed that none of the infants achieved independent sitting nor any other of the subsequent milestones, such as crawling or standing in which all patients had a score of 0 at all times. This was also true with the 2 stronger late onset infants who were at the stronger end of the spectrum.

A score higher than 0 was only achieved in head control (n=13), kicking (n=15) and hand grasp (n=18). It is of interest that even in those items, the maximal score achieved was 1 out of a scale of 4, indicating only partial achievement of the milestone.

10, De Sanctis et al.

Partial head control was only achieved in 11 infants and was reported as wobbling. This was transient in the infants in the main cohort and sustained over several assessments in the 2 stronger infants with late onset. None achieved a constant full head control for more than 15 seconds.

Thirteen infants were able to kick horizontally on at least one assessment but legs did not lift with full antigravity movements at any time, including the 2 stronger infants.

Similarly, although the item exploring hand grasp was not specifically designed to capture changes in weak infants but is mainly assessing development of fine motor skills, only a few infants achieved the ability to use the whole hand and only the 2 stronger infants developed better hand grip.

Overall, when present, the scores of 1 were found in younger infants on their first assessments and, with only one exception, none showed any improvement from 0 to 1 on subsequent evaluations. Therefore, increased survival does not appear to increase the possibility of acquiring developmental milestones over time, or to improving their scores even if a full milestone is not achieved. This finding, in fact, is not surprising as several studies have reported progressive loss of motor neurons in both animal models and humans; using neurophysiological biomarkers, like CMAP and MUNE, severe and substantial postnatal progression of motor denervation has been shown in the first months postnatally in type I SMA. [16]

When we looked at the possible relationship between ventilatory or nutritional support and developmental milestones, the numbers were too small to allow a meaningful statistical analysis but it was obvious that the introduction of gastrostomy or ventilator support was not consistently associated either with higher scores or with a longer persistence of score 1.

This may be explained by the fact that while better standards of care may facilitate wellbeing and increased survival, the need for ventilation or gastrostomy is, in most cases, a

11, De Sanctis et al.

sign that the disease has already progressed and is less likely to be associated with subsequent improvements.

One of the limitations of the study is its retrospective nature; however, data were collected over a limited period of time in centers that were complying with current standards of care. In order to avoid possible bias, the recruitment period was also limited to the time when enrollment for clinical trials had not started in the participating centers as, after that, we would have included only the infants who for some reason, were thought not to be eligible for clinical trials. The relative small number of patients was justified by the exclusion of infants who had only one assessment and then decided to follow palliative care locally. It is of interest, however, that infants who had only a single assessment were generally performing very poorly and none had a score of 2 (data not shown).

Our results suggest that even with current standards of care, motor developmental milestones are rarely acquired, even partially, as part of natural history in type I SMA infants. Even the stronger ones, who had longer preservation of the scores of 1 when compared to the weaker infants with a more typical course, failed to make any further gains after the first evaluation. In future drug intervention studies, type I SMA infants who achieve motor milestones beyond what is described here can be attributed, with a strong probability, as being due to drug effect and not to enhanced standard of care or prolonged survival. Further longitudinal prospective studies, exploring, in more detail, the correlation with standards of care, SMN2 copy numbers, neurophysiology or biomarkers will help to further elucidate the progression and the variability of the disease.

#### Acknowledgments

Roberto De Sanctis: performed HINE assessments, contributed to the study design, data collection and interpretation. Dr. DE SANCTIS reports no disclosures.

12, De Sanctis et al.

Giorgia Coratti: conducted the statistical analysis, data collection and interpretation, and reviewed the manuscript. Dr. CORATTI reports no disclosures.

Amy Pasternak: performed HINE assessments, contributed to the design of the study, data collection and interpretation, and reviewed the manuscript. Dr. PASTERNAK reports no disclosures.

Jacqueline Montes: performed HINE assessments, contributed to the design of the study, data collection and interpretation, and reviewed the manuscript. Dr. MONTES reports no disclosures.

Marika Pane: contributed to the study design, data interpretation and manuscript review.

Dr. PANE reports no disclosures.

Elena S. Mazzone: performed HINE assessments, contributed to the design of the study, data collection and interpretation, and reviewed the manuscript. Dr. MAZZONE reports no disclosures.

Sally Dunaway: performed HINE assessments, contributed to the design of the study, data collection and interpretation, and reviewed the manuscript. Dr. DUNAWAY reports no disclosures.

Rachel Salazar: performed HINE assessments, contributed to the design of the study, data collection and interpretation, and reviewed the manuscript. Dr. SALAZAR reports no disclosures.

Janet Quigley: performed HINE assessments, contributed to the design of the study, data collection and interpretation, and reviewed the manuscript. Dr. QUIGLEY reports no disclosures.

Maria C. Pera: contributed to the study design, data interpretation and manuscript review.

Dr. PERA reports no disclosures.

Laura Antonaci: contributed to the study design, data interpretation and manuscript review.

Dr. ANTONACI reports no disclosures.

13, De Sanctis et al.

Leonardo Lapenta: contributed to the study design, data interpretation and manuscript review. Dr. LAPENTA reports no disclosures.

Allan M Glanzman: performed HINE assessments, contributed to the design of the study, data collection and interpretation, and reviewed the manuscript. Dr. GLANZMAN reports no disclosures.

Francesco Muntoni: contributed to the study design, data interpretation and manuscript review and drafted the manuscript. Dr. MUNTONI reports no disclosures.

Basil T Darras: contributed to the study design, data interpretation and manuscript review.

Dr. DARRAS reports no disclosures.

Darryl C. De Vivo: contributed to the study design, data interpretation and manuscript review and drafted the manuscript. Dr. DE VIVO reports no disclosures.

Richard Finkel: contributed to the study design, data interpretation and manuscript review and drafted the manuscript. Dr. FINKEL reports no disclosures.

Eugenio Mercuri: contributed to the study design, data interpretation and manuscript review and drafted the manuscript. Dr. MERCURI reports no disclosures.

Funding: This study was funded by , Famiglie SMA and Telethon (Italy) (GSP 13002), the SMA Foundation (to PNCR) and SMA Trust (UK).

14, De Sanctis et al.

#### References

- [1] Dubowitz V. Muscle Disorders in Childhood, 2nd edition. London. Saunders; 1995.
- [2] Russman BS. Spinal muscular atrophy: clinical classification and disease heterogeneity. J Child Neurol 2007;22:946-51.
- [3] Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 2014;83:810-7.
- [4] Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol 2012;11:443-52.
- [5] Oskoui M, Levy G, Garland CJ, et al. The changing natural history of spinal muscular atrophy type 1. Neurology 2007;69:1931-6.
- [6] Glanzman AM, Mazzone E, Main M, et al. The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromusc Disord 2010;20:155-61.
- [7] Finkel RS, Hynan LS, Glanzman AM, et al. The test of infant motor performance: reliability in spinal muscular atrophy type I. Pediatr Phys Ther 2008;20:242-6.
- [8] Krosschell KJ, Maczulski JA, Scott C, et al. Reliability and validity of the TIMPSI for infants with spinal muscular atrophy type I. Pediatr Phys Ther 2013;25:140-8; discussion 9.
- [9] Haataja L, Mercuri E, Regev R, et al. Optimality score for the neurologic examination of the infant at 12 and 18 months of age. J Pediatrics 1999;135:153-61.
- [10] Dubowitz L, Dubowitz, V., Mercuri, E. The Neurological assessment of the preterm and full term newborn infant. London: Mc Keith Press; 1999.
- [11] Dubowitz. Chaos in the classification of SMA: a possible resolution. Neuromusc Disord 1995;5:3-5.

15, De Sanctis et al.

- [12] Finkel R, Bertini E, Muntoni F, Mercuri E, Group ESWS. 209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7-9 November 2014, Heemskerk, The Netherlands. Neuromusc Disord 2015;25:593-602.
- [13] Illingworth R. The Development of the Infant and the Young Child: Normal and Abnormal. Edinburgh: Livingstone; 1960.
- [14] Wijnhoven TM, de Onis M, Onyango AW, et al. Assessment of gross motor development in the WHO Multicentre Growth Reference Study. Food and nutrition bulletin 2004;25:S37-45.
- [15] Romeo DM, Ricci D, Brogna C, Mercuri E. Use of the Hammersmith Infant Neurological Examination in infants with cerebral palsy: a critical review of the literature. Dev Med Child Neurol 2016;58:240-5.
- [16] Swoboda KJ, Prior T, Scott C, et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol 2005;57:704-12.

#### Figure legend

- Figure 1: HINE scoring module illustrating the motor developmental milestones.
- Figure 2: Longitudinal data of the item assessing the ability to control the head in 24 typical type 1 SMA infants (from number 1 to 24) and in 2 stronger type 1 infants with late onset (25-26, shaded). Each line represents the different assessment in the same patient linked by a dotted line.
- •=score 0, ○= score 1, V= ventilation; G= gastrostomy; T= tracheostomy).

  The seven weakest patients with onset within the first week (type 1 A or 1.1 according to Dubowitz), were not added to the figure as they all had a score of 0 in all assessments.
- Figure 3: Longitudinal data of the item assessing voluntary grasp in 24 typical type 1 SMA infants (from number 1 to 24) and in 2 type 1 infants with late onset (25-26, shaded). Each line represents the different assessment in the same patient linked by a dotted line

16, De Sanctis et al.

•=score 0, ○= score 1, V= ventilation; G= gastrostomy; T= tracheostomy).

The seven patients with onset within the first week (type 1 A or 1.1 according to Dubowitz), were not added to the figure as they all had a score of 0in all assessments

Figure 4: Longitudinal data of the item assessing ability to kick in 24 typical type 1 SMA infants (from number 1 to 24) and in 2 type 1 infants with late onset (25-26, shaded). Each line represents the different assessment in the same patient linked by a dotted line

•=score 0,  $\circ$ = score 1, V= ventilation; G= gastrostomy; T= tracheostomy).

The seven patients with onset within the first week (type 1 A or 1.1 according to Dubowitz), were not added to the figure as they all had a score of 0 in all assessments.

17, De Sanctis et al.

Figure 1.

Head	Unable to	Wobbles	Maintained upright		
control	maintain head		all the time		
	upright	normal up to 4m	normal from 5m		
Sitting	normal up to 3m Cannot sit	With support at	Props	Stable sit	Pivots (rotates)
Sitting	Carriot Sit	hips	Flops	Stable Sit	FIVUIS (TUILAILES)
				<b>A</b>	
		الح	<b>√</b> €	<b>Y</b>	Y
		<b>✓</b>	<u> </u>		200
		normal at 4m	normal at 6m	normal at 7-8m	normal at 9m
	No secon	Llaca whala hand	Indov finance and	Dinger groop	
Voluntary	No grasp	Uses whole hand	Index finger and thumb but	Pincer grasp	
grasp –			immature grasp		
note side			ataro graop		
Ability to	No kicking	Kicks horizontally	Upward (vertically)	Touches leg	Touches toes
kick in		but	a\		
supine		legs do not lift	(D23)	A l	ar\
			normal at 3m	<u> </u>	normal at F. 6m
Dallin n	No vallina	Delling to side	Drana to aunina	normal at 4-5m	normal at 5-6m
Rolling	No rolling	Rolling to side	Prone to supine	Supine to prone	
		(normal at 4m)	(normal at 6 m)	(normal at 6 m)	
Crawling	Does not lift head	On elbow	On outstretched	Crawling flat on	Crawling on hands
or bottom			hand	abdomen	and knees
shuffling		<b>(</b> -)			(P)
		<b>₹</b>			- J
		(normal at 2 m)			
	D	(normal at 3 m)	(normal at 4m)	(normal at 8m)	(normal at 10m)
Ot an alim a	Does not support weight	Supports weight	Stands with support	Stands unaided	
Standing	weigiit	(normal at 4m)	Support		
		(Horman at IIII)	(normal at 7m)	(normal at 12m)	
Walking		Bouncing	Cruising (walks	Walking	
		Y W	holding on)	independently	
		(normal at 6m)	(normal at 12m)	(normal by 15m)	
		(Hollial at Oll)	(HOIIIIai at 12III)	(Hollian by Folli)	